FindTrial
Sign In

Al18F-NOTA-LM3 PET/CT imaging in somatostatin receptor-positive tumors

Al18F-NOTA-LM3 PET/CT imaging in somatostatin receptor-positive tumors

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122121
Enrollment
Unknown
Registered
2026-04-09
Start date
2023-03-23
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), pheochromocytomas, paragangliomas, tumor-induced osteomalacia (TIO), and other somatostatin receptor-positive tumors

Interventions

Patients with suspected or confirmed neuroendocrine tumors:18AlF-NOTA-LM3 PET/CT

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Clinical suspicion of neuroendocrine tumors based on clinical manifestations and other imaging findings, with surgical or biopsy pathology already obtained, or with planned surgery/biopsy to obtain final pathological diagnosis. 2. Obtain written informed consent and be able to comply with follow-up. 3. Age range: 18-70 years old.

Exclusion criteria

Exclusion criteria: 1.Pregnant and lactating women; 2.Patients with renal failure; 3.Difficult to receive further treatment due to their severe condition.

Design outcomes

Primary

MeasureTime frame
Tumor uptake level (expressed as SUV value);—

Countries

China

Contacts

Public ContactLi Huo

Peking Union Medical College Hospital

huoli@pumch.cn+86 10 69155513

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026